Drugs / COM503
last change Jan 2025 re-read 2 minutes ago

COM503

Developed for
cancer
Investigated by
Compugen Ltd · Gilead Sciences

Trials 1 · a red edge is where a trial was stopped

202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06759649 Jan 2025 → Nov 2027 expected cancer Compugen Ltd Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as COM503 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06759649
Route Intravenous Intravenous Infusion” NCT06759649